<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
<channel>
	<title>SEETREAT PTY LTD</title>
	<language>en_US</language>
	<generator>PRN Asia</generator>
	<description><![CDATA[we tell your story to the world!]]></description>
		<item>
		<title>GenesisCare and SeeTreat to bring personalised Offline Adaptive Monitoring to more than 40 radiation oncology centres across Australia</title>
		<author></author>
		<pubDate>2026-05-14 15:00:00</pubDate>
		<description><![CDATA[SYDNEY, May 14, 2026 /PRNewswire/ -- Leading Australian cancer care provider, 
GenesisCare, is pleased to be collaborating with SeeTreat to enable suitable 
cancer patients access to the latest technology in offline adaptive treatment 
assessment. SeeTreat's ART.1 software will be rolled out at GenesisCare from 
July 2026 to support automated, adaptive treatment evaluation for eligible 
patients.

 <https://mma.prnasia.com/media2/2978855/Supporting_Image.html> 
SeeTreat ART.1

GenesisCare Chief Medical Officer, Dr Marcus Dreosti, explains that "whilst 
radiation treatment is proven to be a safe and highly effective cancer 
treatment, unwanted toxicities and side effects can occur due to changes in a 
patient's anatomy over the course of treatment. Optimising treatment post 
commencement, called 'adaptive radiotherapy', is labour intensive and complex. 
We're excited that through this collaboration with SeeTreat, we now have the 
opportunity to make adaptive radiotherapy more accessible for patients across 
our Australian network."

GenesisCare's decision to implement the SeeTreat ART.1 tool follows a 
multidisciplinary study of the software on 64 head and neck, breast, and 
prostate cancer patients treated on their mixed vendor linac platform assessing 
accuracy, efficiency and patient impact. The study showed significant potential 
benefits to standardising and scaling adaptive workflows, providing actionable 
insights to clinicians when they need it.

Radiation Oncologist, Dr Melanie Jackson, shares: "ART.1 is proving to be an 
easy-to-use tool to help me identify which of my patients would benefit from a 
new treatment plan and when this is optimal. The efficiency of the software and 
personalisation of care ensures we match our clinical team's effort and 
valuable resource time to achieve the best possible patient outcomes." 

SeeTreat CEO and Founder, Dr Trang Nguyen said "GenesisCare is a truly 
patient-centric and innovative organisation with passionate doctors and 
clinical staff constantly striving to deliver the best care possible. Working 
with the GenesisCare team is a pleasure and we're proud to be collaborating 
with the group." 

SeeTreat's ART.1 software has UKCA mark, CE mark, Australian ARTG 
registration and is FDA pending.

About SeeTreat 

SeeTreat is doctor backed, physics led, software medical device company 
founded in 2023, led by Dr Trang Nguyen, Antonia Dalton and Professor Paul 
Keall. Our vision is to reduce the burden of cancer through broadly accessible 
software technology improving quality and accuracy of treatment. SeeTreat is a 
global company with a current install base in the UK, Europe, USA and 
Australia. 

For more information visit https://www.seetreatmedical.com/ 
<https://www.seetreatmedical.com/> and follow SeeTreat on LinkedIn 
https://www.linkedin.com/company/seetreat-medical 
<https://www.linkedin.com/company/seetreat-medical/mycompany/>

About GenesisCare

GenesisCare is a proudly Australian-run cancer care provider, specialising in 
radiation therapy with a growing footprint in medical oncology, theranostics 
and personalised medicine. Our relentless pursuit for better care is reflected 
in our advanced treatment techniques, technology and contemporary service 
experience.

Our dedicated research team partners globally to be first movers in bringing 
clinical innovations to patients close to home. 

Over 35,000 people a year entrust us with their care across more than 50 
locations nationally.

]]></description>
		<detail><![CDATA[<p><span class="legendSpanClass">SYDNEY</span>, <span class="legendSpanClass">May 14, 2026</span> /PRNewswire/ -- Leading Australian cancer care provider, GenesisCare, is pleased to be collaborating with SeeTreat to enable suitable cancer patients access to the latest technology in offline adaptive treatment assessment. SeeTreat's ART.1 software will be rolled out at GenesisCare from July 2026 to support automated, adaptive treatment evaluation for eligible patients.</p> 
<div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> 
 <p style="TEXT-ALIGN: center; WIDTH: 100%"> <a href="https://mma.prnasia.com/media2/2978855/Supporting_Image.html" target="_blank" rel="nofollow" style="color: #0000FF"> <img src="https://mma.prnasia.com/media2/2978855/Supporting_Image.jpg?p=medium600" title="SeeTreat ART.1" alt="SeeTreat ART.1" /> </a> <br /><span>SeeTreat ART.1</span></p> 
</div> 
<p>GenesisCare Chief Medical Officer, Dr Marcus Dreosti, explains that &quot;whilst radiation treatment is proven to be a safe and highly effective cancer treatment, unwanted toxicities and side effects can occur due to changes in a patient's anatomy over the course of treatment. Optimising treatment post commencement, called 'adaptive radiotherapy', is labour intensive and complex. We're excited that through this collaboration with SeeTreat, we now have the opportunity to make adaptive radiotherapy more accessible for patients across our Australian network.&quot;</p> 
<p>GenesisCare's decision to implement the SeeTreat ART.1 tool follows a multidisciplinary study of the software on 64 head and neck, breast, and prostate cancer patients treated on their mixed vendor linac platform assessing accuracy, efficiency and patient impact. The study showed significant potential benefits to standardising and scaling adaptive workflows, providing actionable insights to clinicians when they need it.</p> 
<p>Radiation Oncologist, Dr Melanie Jackson, shares: &quot;ART.1 is proving to be an easy-to-use tool to help me identify which of my patients would benefit from a new treatment plan and when this is optimal. The efficiency of the software and personalisation of care ensures we match our clinical team's effort and valuable resource time to achieve the best possible patient outcomes.&quot;&nbsp;</p> 
<p>SeeTreat CEO and Founder, Dr Trang Nguyen said &quot;GenesisCare is a truly patient-centric and innovative organisation with passionate doctors and clinical staff constantly striving to deliver the best care possible. Working with the&nbsp;GenesisCare team is a pleasure and we're proud to be collaborating with the group.&quot;&nbsp;</p> 
<p>SeeTreat's ART.1 software has UKCA mark, CE mark, Australian ARTG registration&nbsp;and is FDA pending.</p> 
<p><b>About SeeTreat</b>&nbsp;</p> 
<p>SeeTreat is doctor backed, physics led, software medical device company founded in 2023, led by Dr Trang Nguyen, Antonia Dalton and Professor Paul Keall. Our vision is to reduce the burden of cancer through broadly accessible software technology improving quality and accuracy of treatment.&nbsp;SeeTreat is a global company with a current install base in the UK, Europe, USA and Australia.&nbsp;</p> 
<p>For more information visit&nbsp;<a href="https://www.seetreatmedical.com/" target="_blank" rel="nofollow" style="color: #0000FF">https://www.seetreatmedical.com/</a>&nbsp;and follow SeeTreat on LinkedIn <a href="https://www.linkedin.com/company/seetreat-medical/mycompany/" target="_blank" rel="nofollow" style="color: #0000FF">https://www.linkedin.com/company/seetreat-medical</a></p> 
<p><b>About GenesisCare</b></p> 
<p>GenesisCare is a proudly Australian-run cancer care provider, specialising in radiation therapy with a growing footprint in medical oncology, theranostics and personalised medicine. Our relentless pursuit for better care is reflected in our advanced treatment techniques, technology and contemporary service experience.</p> 
<p>Our dedicated research team partners globally to be first movers in bringing clinical innovations to patients close to home.&nbsp;</p> 
<p>Over 35,000 people a year entrust us with their care across more than 50 locations nationally.</p>]]></detail>
		<source><![CDATA[<br/>GenesisCare<br/>SeeTreat]]></source>
	</item>
	
</channel>
</rss>